[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Fallatah, 2016 - Google Patents

Combination of immune stimulatory strategies to promote anti-tumour immunity

Fallatah, 2016

View PDF
Document ID
5732028557324304659
Author
Fallatah M
Publication year

External Links

Snippet

CD8+ T cells can kill cancer cells but are tightly regulated by receptors that confer positive or negative signals. Members of the tumour necrosis factor receptor superfamily (TNFRSF) can improve the responses of antigen-specific CD8+ T cells by enhancing their survival …
Continue reading at eprints.soton.ac.uk (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
US20240293461A1 (en) Methods of Treating T Cell Exhaustion by Inhibiting or Modulating T Cell Receptor Signaling
EP1434596B1 (en) Enhancement of immune responses by agonist 4-1bb-antibodies
JP6074435B2 (en) Mutant CTLA4 gene-transferred T cell and anticancer immunotherapeutic composition containing the same
US9238064B2 (en) Allogeneic cancer cell-based immunotherapy
WO2019136305A1 (en) Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer
US20190330303A1 (en) Cell compositions and methods for cancer therapy
JP2005528892A (en) Activation of tumor-reactive lymphocytes via antibodies or genes that recognize CD3 or 4-1BB
JP2022531911A (en) Manipulated immune cells targeting BCMA and their use
CN115135674A (en) Dendritic cell activating chimeric antigen receptor and uses thereof
Muraoka et al. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells
CN113396215A (en) Chimeric Antigen Receptor (CAR) -expressing Myeloid Infiltrating Lymphocytes (MILs), methods of making the same, and methods of use in therapy
Adler et al. Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation
Morandi et al. Novel immunotherapeutic approaches for neuroblastoma and malignant melanoma
WO2023278641A1 (en) Immune cells engineered to promote thanotransmission and uses thereof
Fallatah Combination of immune stimulatory strategies to promote anti-tumour immunity
WO2024060140A1 (en) Egfrviii chimeric antigen receptor and use thereof
Emerson The Role, Function, and Generation of Eomeshi CD8+ T Cells in OX40 and CTLA-4 Targeted Cancer Immunotherapy
Stringhini Direct and Indirect Harnessing of Cytotoxic CD8+ T Lymphocytes for Cancer Therapy: Adoptive Cell Therapy Versus Immunocytokines
AU2003243138A1 (en) Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb
Rotte et al. Promising immunotherapeutic approaches in clinical trials
Kansy et al. Immunology of Head and Neck Cancer
Garcia et al. Cancer immunology and novel strategies for immunotherapy
Crowther Immunotherapy of murine B-cell lymphoma mediated by agonistic anti-CD40 antibody: role of co-stimulation in generation of CD8+ CTL
Erkes Exploiting Murine Cytomegalovirus as an Anti-Tumor Therapy and Model for Virus-Specific Tumor Infiltrating Lymphocytes
Draghiciu Novel strategies for enhancing the efficacy of therapeutic immunization against cancer